Cargando…
Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase
Multiple sclerosis (MS) is a chronic autoimmune disease driven by T and B lymphocytes. The remyelination failure and neurodegeneration results in permanent clinical disability in MS patients. A desirable therapy should not only modulate the immune system, but also promote neuroprotection and remyeli...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716455/ https://www.ncbi.nlm.nih.gov/pubmed/34975892 http://dx.doi.org/10.3389/fimmu.2021.792465 |
_version_ | 1784624327278198784 |
---|---|
author | Hao, Wenlin Luo, Qinghua Menger, Michael D. Fassbender, Klaus Liu, Yang |
author_facet | Hao, Wenlin Luo, Qinghua Menger, Michael D. Fassbender, Klaus Liu, Yang |
author_sort | Hao, Wenlin |
collection | PubMed |
description | Multiple sclerosis (MS) is a chronic autoimmune disease driven by T and B lymphocytes. The remyelination failure and neurodegeneration results in permanent clinical disability in MS patients. A desirable therapy should not only modulate the immune system, but also promote neuroprotection and remyelination. To investigate the neuroprotective effect of CD52 antibody in MS, both C57BL/6J and SJL mice with experimental autoimmune encephalomyelitis (EAE) were treated with CD52 antibody at the peak of disease. Treatment with CD52 antibody depleted T but not B lymphocytes in the blood, reduced the infiltration of T lymphocytes and microglia/macrophages in the spinal cord. Anti-CD52 therapy attenuated EAE scores during the recovery phase. It protected neurons immediately after treatment (within 4 days) as shown by reducing the accumulation of amyloid precursor proteins. It potentially promoted remyelination as it increased the number of olig2/CC-1-positive mature oligodendrocytes and prevented myelin loss in the following days (e.g., 14 days post treatment). In further experiments, EAE mice with a conditional knockout of BDNF in neurons were administered with CD52 antibodies. Neuronal deficiency of BDNF attenuated the effect of anti-CD52 treatment on reducing EAE scores and inflammatory infiltration but did not affect anti-CD52 treatment-induced improvement of myelin coverage in the spinal cord. In summary, anti-CD52 therapy depletes CD4-positive T lymphocytes, prevents myelin loss and protects neurons in EAE mice. Neuronal BDNF regulates neuroprotective and anti-inflammatory effect of CD52 antibody in EAE mice. |
format | Online Article Text |
id | pubmed-8716455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87164552021-12-31 Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase Hao, Wenlin Luo, Qinghua Menger, Michael D. Fassbender, Klaus Liu, Yang Front Immunol Immunology Multiple sclerosis (MS) is a chronic autoimmune disease driven by T and B lymphocytes. The remyelination failure and neurodegeneration results in permanent clinical disability in MS patients. A desirable therapy should not only modulate the immune system, but also promote neuroprotection and remyelination. To investigate the neuroprotective effect of CD52 antibody in MS, both C57BL/6J and SJL mice with experimental autoimmune encephalomyelitis (EAE) were treated with CD52 antibody at the peak of disease. Treatment with CD52 antibody depleted T but not B lymphocytes in the blood, reduced the infiltration of T lymphocytes and microglia/macrophages in the spinal cord. Anti-CD52 therapy attenuated EAE scores during the recovery phase. It protected neurons immediately after treatment (within 4 days) as shown by reducing the accumulation of amyloid precursor proteins. It potentially promoted remyelination as it increased the number of olig2/CC-1-positive mature oligodendrocytes and prevented myelin loss in the following days (e.g., 14 days post treatment). In further experiments, EAE mice with a conditional knockout of BDNF in neurons were administered with CD52 antibodies. Neuronal deficiency of BDNF attenuated the effect of anti-CD52 treatment on reducing EAE scores and inflammatory infiltration but did not affect anti-CD52 treatment-induced improvement of myelin coverage in the spinal cord. In summary, anti-CD52 therapy depletes CD4-positive T lymphocytes, prevents myelin loss and protects neurons in EAE mice. Neuronal BDNF regulates neuroprotective and anti-inflammatory effect of CD52 antibody in EAE mice. Frontiers Media S.A. 2021-12-16 /pmc/articles/PMC8716455/ /pubmed/34975892 http://dx.doi.org/10.3389/fimmu.2021.792465 Text en Copyright © 2021 Hao, Luo, Menger, Fassbender and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Hao, Wenlin Luo, Qinghua Menger, Michael D. Fassbender, Klaus Liu, Yang Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase |
title | Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase |
title_full | Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase |
title_fullStr | Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase |
title_full_unstemmed | Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase |
title_short | Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase |
title_sort | treatment with cd52 antibody protects neurons in experimental autoimmune encephalomyelitis mice during the recovering phase |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716455/ https://www.ncbi.nlm.nih.gov/pubmed/34975892 http://dx.doi.org/10.3389/fimmu.2021.792465 |
work_keys_str_mv | AT haowenlin treatmentwithcd52antibodyprotectsneuronsinexperimentalautoimmuneencephalomyelitismiceduringtherecoveringphase AT luoqinghua treatmentwithcd52antibodyprotectsneuronsinexperimentalautoimmuneencephalomyelitismiceduringtherecoveringphase AT mengermichaeld treatmentwithcd52antibodyprotectsneuronsinexperimentalautoimmuneencephalomyelitismiceduringtherecoveringphase AT fassbenderklaus treatmentwithcd52antibodyprotectsneuronsinexperimentalautoimmuneencephalomyelitismiceduringtherecoveringphase AT liuyang treatmentwithcd52antibodyprotectsneuronsinexperimentalautoimmuneencephalomyelitismiceduringtherecoveringphase |